In vivo and in vitro antitumor activity of butyroyloxymethyl‐diethyl phosphate (AN‐7), a histone deacetylase inhibitor, in human prostate cancer
暂无分享,去创建一个
Z. Malik | A. Nudelman | S. Cutts | A. Rephaeli | D. Phillips | M. Entin-Meer | N. Tarasenko | Inesa Levovich | D. Blank-Porat
[1] T. McCaffrey,et al. A rapid fluorometric DNA assay for the measurement of cell density and proliferation in vitro , 1988, In Vitro Cellular & Developmental Biology.
[2] Y. Bang,et al. Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.
[3] A. Nudelman,et al. The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters. , 2005, Journal of medicinal chemistry.
[4] A. Nudelman,et al. Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells , 2005, Journal of Cancer Research and Clinical Oncology.
[5] A. Nudelman,et al. Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells , 2005, Journal of Cancer Research and Clinical Oncology.
[6] J. Arts,et al. Histone Deacetylase Inhibitors: From Chromatin Remodelling to Experimental Cancer Therapeutics , 2005 .
[7] A. Nudelman,et al. Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation. , 2004, Oncology research.
[8] A. Wozniak,et al. Chronic Oral Administration of CI-994: A Phase I Study , 2004, Investigational New Drugs.
[9] Cesario Z. Cerna,et al. Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units , 2004, Investigational New Drugs.
[10] J. Arts,et al. Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. , 2003, Current medicinal chemistry.
[11] L. Schwartz,et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] J. Holaday,et al. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo , 2003, The Prostate.
[13] L. Sokoll,et al. Prostate‐specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo , 2003, The Prostate.
[14] R. Tarone,et al. Trends in prostate cancer mortality among black men and white men in the United States , 2003, Cancer.
[15] J. Nemunaitis,et al. Phase I Study of Oral CI‐994 in Combination with Gemcitabine in Treatment of Patients with Advanced Cancer , 2003, Cancer journal.
[16] E. Brass. Pivalate-Generating Prodrugs and Carnitine Homeostasis in Man , 2002, Pharmacological Reviews.
[17] M. Diccianni,et al. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. , 2002, Blood.
[18] A. Kalita,et al. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. , 2002, Cancer research.
[19] C. Britten,et al. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] S. Bates,et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] A. Nudelman,et al. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). , 2001, Cancer research.
[22] B. Cairns. Emerging roles for chromatin remodeling in cancer biology. , 2001, Trends in cell biology.
[23] Y. Oda,et al. The accumulation of angiostatin-like fragments in human prostate carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] S. Sampson,et al. Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. , 2001, European journal of medicinal chemistry.
[25] A. Giatromanolaki,et al. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] A. Nudelman,et al. Uptake of pivaloyloxymethyl butyrate into leukemic cells and its intracellular esterase-catalyzed hydrolysis , 2000, Journal of Cancer Research and Clinical Oncology.
[27] M. Gleave,et al. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. , 2000, Cancer research.
[28] R A Rifkind,et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.
[29] J. Mariadason,et al. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. , 2000, Cancer research.
[30] A. Nudelman,et al. Prodrugs of butyric acid from bench to bedside: Synthetic design, mechanisms of action, and clinical applications , 2000 .
[31] U. Weidle,et al. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. , 2000, Anticancer research.
[32] R. Kontermann,et al. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen , 1999, British Journal of Cancer.
[33] J. Holaday,et al. Antiangiogenic activity of prostate-specific antigen. , 1999, Journal of the National Cancer Institute.
[34] S. Schwartz,et al. A new human prostate carcinoma cell line, 22Rv1 , 1999, In Vitro Cellular & Developmental Biology - Animal.
[35] G. Wilding,et al. Drug development in prostate cancer. , 1999, Seminars in oncology.
[36] A. Wolffe. Sinful repression , 1997, nature.
[37] Y. Honma,et al. An anti-cancer derivative of butyric acid (pivalyloxmethyl buterate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukaemia cells. , 1997, British Journal of Cancer.
[38] A. Nudelman,et al. Esterase inhibitors diminish the modulation of gene expression by butyric acid derivative, pivaloyloxymethyl butyrate (AN-9). , 1996, Israel journal of medical sciences.
[39] C. Van Lint,et al. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. , 1996, Gene expression.
[40] A. Nudelman,et al. Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL‐60 leukemic cell line , 1994, International journal of cancer.
[41] A. Nudelman,et al. Rapid alteration of c‐myc and c‐jun expression in leukemic cells induced to differentiate by a butyric acid prodrug , 1993, FEBS letters.
[42] A. Nudelman,et al. Novel anticancer prodrugs of butyric acid. 2. , 1992, Journal of medicinal chemistry.
[43] A. Nudelman,et al. Derivatives of butyric acid as potential anti‐neoplastic agents , 1991, International journal of cancer.